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Abstract
The adverse metabolic effects of prescribed and endogenous glucocorticoid excess, 
‘Cushing’s syndrome’, create a significant health burden. While skeletal muscle atrophy 
and resultant myopathy is a clinical feature, the molecular mechanisms underpinning 
these changes are not fully defined. We have characterized the impact of glucocorticoids 
upon key metabolic pathways and processes regulating muscle size and mass including: 
protein synthesis, protein degradation, and myoblast proliferation in both murine 
C2C12 and human primary myotube cultures. Furthermore, we have investigated the 
role of pre-receptor modulation of glucocorticoid availability by 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) in these processes. Corticosterone (CORT) decreased 
myotube area, decreased protein synthesis, and increased protein degradation in murine 
myotubes. This was supported by decreased mRNA expression of insulin-like growth 
factor (IGF1), decreased activating phosphorylation of mammalian target of rapamycin 
(mTOR), decreased phosphorylation of 4E binding protein 1 (4E-BP1), and increased 
mRNA expression of key atrophy markers including: atrogin-1, forkhead box O3a 
(FOXO3a), myostatin (MSTN), and muscle-ring finger protein-1 (MuRF1). These findings 
were endorsed in human primary myotubes, where cortisol also decreased protein 
synthesis and increased protein degradation. The effects of 11-dehydrocorticosterone 
(11DHC) (in murine myotubes) and cortisone (in human myotubes) on protein 
metabolism were indistinguishable from that of CORT/cortisol treatments. Selective 
11β-HSD1 inhibition blocked the decrease in protein synthesis, increase in protein 
degradation, and reduction in myotube area induced by 11DHC/cortisone. Furthermore, 
CORT/cortisol, but not 11DHC/cortisone, decreased murine and human myoblast 
proliferative capacity. Glucocorticoids are potent regulators of skeletal muscle protein 
homeostasis and myoblast proliferation. Our data underscores the potential use of 
selective 11β-HSD1 inhibitors to ameliorate muscle-wasting effects associated with 
glucocorticoid excess.
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Introduction
The pathophysiological effects of glucocorticoids (GCs) 
are well described and impact upon almost all organ 
systems within the body. This is highlighted in patients 
with GC excess, Cushing’s syndrome, characterized 
by central obesity, hypertension, skeletal myopathy, 
and insulin resistance. In addition, up to 2.5% of the 
population is taking prescribed GCs, and their side effects 
represent a considerable clinical burden (Wei et al. 2004, 
 Hassan-Smith et al. 2012).
GC availability and action depend not only 
on circulating levels, but also on the tissue-specific 
intracellular metabolism by 11β-hydroxysteroid 
dehydrogenases (11β-HSDs) (Stewart & Krozowski 
1999). Skeletal muscle expresses 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1), which converts 
inactive 11-dehydrocorticosterone (11DHC) to active 
corticosterone (CORT) (cortisone and cortisol in 
humans, respectively) (Morgan et al. 2009). In contrast to 
11β-HSD2, which plays no physiological role in this 
tissue, 11β-HSD1 has been shown to regulate both insulin 
sensitivity and lipid metabolism of skeletal muscle (Morgan 
et  al. 2009, 2013). Furthermore, overexpression has been 
described in rodent and human models of type 2 diabetes 
and age-associated muscle weakness (Whorwood et  al. 
2002, Abdallah et al. 2005, Zhang et al. 2009, Kilgour et al. 
2013, Hassan-Smith et  al. 2015), and selective 11β-HSD1 
inhibitors have consistently demonstrated an ability to 
cause insulin sensitization in preclinical and clinical studies 
(Alberts et  al. 2003, Bhat et  al. 2008). We have recently 
shown that deletion of 11β-HSD1 in mice protects against 
the adverse side effects associated with both active and 
inactive circulatory GC excess, including skeletal myopathy; 
highlighting 11β-HSD1 as a potential therapeutic target in 
the treatment of Cushing’s syndrome (Morgan et al. 2014).
Muscle mass is tightly controlled through the regula-
tion of protein metabolism, myoblast proliferation, and 
myocyte differentiation – all vital processes in the repair 
and maintenance of healthy muscle tissue. Mammalian 
target of rapamycin (mTOR) is a central regulator of 
protein synthesis, regulating numerous components 
including the initiation and elongation factors (Thoreen 
et al. 2012). The converse, protein degradation is regulated 
by components of the E3 ubiquitin proteosomal system 
(UPS), including muscle-ring finger protein-1 (MuRF1) 
and atrogin-1, both target cellular proteins to the protea-
some for hydrolysis (Lecker et al. 2006).
It is well established that GCs drive muscle 
atrophy through modulation of protein metabolism 
(McGrath & Goldspink 1982, Savary et  al. 1998, Biedasek 
et  al. 2011). However, the precise molecular mechanisms 
underpinning GC action, and the role of pre-receptor 
GC metabolism by 11β-HSD1 in the regulation of 
intramyocellular protein metabolism and myoblast 
proliferation have not been fully explored. Therefore, we 
have characterized the effects of both active and inactive 
GC treatment, as well as a selective 11β-HSD1 inhibitor, on 
muscle myotube area, intramyocellular protein synthesis, 
protein degradation, and myoblast proliferation in a rodent 
skeletal muscle cell line and human primary muscle cultures.
Research design and methods
Cell culture
Murine C2C12 myoblasts (European Collection of Cell 
Cultures, Salisbury, UK) were grown in DMEM (PAA 
Laboratories, Somerset, UK) supplemented with 10% 
fetal bovine serum (FBS) (37°C, 5% CO2). Cells were 
grown to 60–70% confluence before differentiation 
(initiated by replacing growth media with DMEM with 
5% horse serum). After 8 days, myoblasts fuse to form 
multinucleated myotubes.
Primary human myoblasts were obtained from Promo-
Cell (Heidelberg, Germany). Myoblasts were cultured to 
80% confluence, as per the manufacturer’s guidelines 
using the supplied media. Once confluent, growth media 
was changed to a chemically defined differentiation 
media (PromoCell) and cells differentiated for 8 days to 
form myotubes.
Before treatment, all cells were cultured for 4 h in serum-
free medium without additives. Specific treatments (concen-
trations and duration) are described in the Results section. 
The selective 11β-HSD1 inhibitor, PF-877423, was provided 
through material transfer agreements with Pfizer Global 
R&D (La Jolla, CA, USA) and its detailed potency has been 
described previously (Bujalska et al. 2008). Sigma supplied all 
reagents unless otherwise stated. The number of replicates 
used in each experiment is shown in the figure legends.
Measurement of myotube area
Myotube cultures were photographed under a phase 
contrast microscope at 4× magnification following 
24 h treatments. The areas were measured in a total of 
40 myotubes from multiple random fields using ImageJ 
software (NIH). The observer was blinded to the treatment 
information at the time of analysis.
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Measurement of protein degradation
Rates of protein degradation were determined by 
measuring the release of trichloroacetic acid (TCA) and 
soluble radioactivity from cellular proteins pre-labeled 
with [3H]tyrosine, as described previously (Menconi et al. 
2008). After completing differentiation, myotubes were 
labeled with 1.0 μCi/mL of l-[3,5-3H]tyrosine (PerkinElmer) 
for 48 h in DMEM containing 2% FBS. Cells were then 
treated for 24 h with treatments in DMEM containing 
2 mM unlabeled tyrosine. The culture medium was then 
transferred into a microcentrifuge tube containing 100 μL 
of bovine serum albumin (10 mg/mL), and TCA was 
added to a final concentration of 10% (wt/vol). Samples 
were incubated at 4°C for 1 h, followed by centrifugation 
for 5 min. The supernatant was used for determination of 
TCA-soluble radioactivity. The protein precipitates were 
dissolved with a tissue solubilizer (Solvable, PerkinElmer). 
Cell monolayers were washed with ice-cold phosphate-
buffered saline (PBS) and solubilized with 0.5 M  NaOH 
containing 0.1% Triton X-100. Radioactivity in the cell 
monolayer and TCA-soluble and -insoluble fractions 
were measured using a Packard TRI-CARB 1600 TR liquid 
scintillation analyzer (Perkin-Elmer). Protein degradation 
was expressed as the percentage protein degraded over 
the 24 h period and was calculated as 100 times the 
TCA-soluble radioactivity in the medium divided by 
the TCA-soluble plus the TCA-insoluble radioactivity in 
the medium plus the radioactivity in the cell layer.
Measurement of protein synthesis
Rates of protein synthesis were determined by measuring 
the [3H]tyrosine incorporated into cellular proteins, as 
described previously (Menconi et al. 2008). Differentiated 
myotubes were treated for 48 h with treatments. During 
the last hour of incubation, myotubes were incubated with 
2.0 μCi/mL of l-[3,5-3H]tyrosine in DMEM containing 2% 
FBS and 200 mM unlabeled tyrosine. After incubation, 
the medium was removed and the cell monolayers were 
harvested in 10% TCA. The TCA-precipitated proteins 
were washed several times and then solubilized with 
0.1 N NaOH containing 1% Triton X-100. Radioactivity 
and protein levels were measured in aliquots from the 
solubilized proteins.
Proliferation assay
Myoblast proliferation was assessed using the Celltiter 
96 aqueous one solution cell proliferation assay kit 
(Promega), which is a non-radioactive colorimetric 
method for determining the number of viable cells in 
culture. The assay is composed of a tetrazolium compound 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-H-tetrazolium, inner salt, MTS) and an 
electron-coupling reagent (phenazine methosulfate (PMS)). 
Myoblasts were trypsinized and counted, before seeding at a 
concentration of approximately 1000 cells per well in 96-well 
plates (final volume: 100 μL), and incubated at 37°C, 5% CO2 
for 24 h. Treatments were added to the culture media and the 
cells were further incubated at 37°C, 5% CO2 for 48 h. The 
proliferation assay was subsequently performed according 
to the manufacturer’s protocol. Incubation with IGF1, a 
known activator of myoblast proliferation (Milasincic et al. 
1996), was used as a positive control in these experiments. 
Selected results generated using the above methodology 
were validated using a 5-bromo-2′-deoxyuridine (BrdU) 
Cell Proliferation Assay Kit (Cell Signaling). The assay was 
performed according to the manufacturer’s protocol using 
similar seeding densities and conditions described above.
11β-HSD1 enzyme assays
Briefly, intact cell monolayers were incubated for 2 h 
at 37°C with 100 nM 11DHC and tracer amounts of 
[3H]-11DHC (synthesized in-house (Bujalska et al. 2002)). 
Steroids were then extracted from the culture media 
using dichloromethane, separated using a mobile phase 
consisting of ethanol and chloroform (8:92) by thin 
layer chromatography and scanned using a Bioscan 3000 
image analyzer (Lablogic, Sheffield, UK). Protein levels 
were assayed using a commercially available kit (Bio-Rad), 
and activity expressed as pmol of CORT generated/mg of 
protein/h.
RNA extraction and real-time PCR
Total RNA was extracted from tissue and cells using 
the Tri-Reagent system. RNA integrity was assessed by 
electrophoresis on 1% agarose gel. Concentration was 
determined spectrophotometrically at an optical density 
of (OD)260. In a 50 μL volume, 500 ng of total RNA were 
incubated with 250 μM random hexamers, 500 μM 
dNTPs, 20 U RNase inhibitor, 63 U multiscribe reverse 
transcriptase, 5.5 mM MgCl and 1× reaction buffer. The 
reverse transcription reaction was carried out at 25°C 
for 10 min, 48°C for 30 min before the reaction was 
terminated by heating to 95°C for 5 min. mRNA levels 
were determined using an ABI 7500 sequence detection 
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system (Applied Biosystems). Reactions were performed in 
singleplex in 10 μL volumes on 96-well plates in a reaction 
buffer containing 2× TaqMan Universal PCR Master Mix 
(Applied Biosystems). Primers and probes were supplied 
by Applied Biosystems as premade ‘assay on demands’. All 
reactions were normalized against the housekeeping gene 
18S  rRNA, provided as a pre-optimized control probe. 
All target genes were labeled with 6-carboxyfluorescein 
(6-FAM), and the reference gene with 2′-chloro-7′phenyl-
1,4-dichloro-6-carboxy-fluorescein (VIC). The reaction 
conditions were as follows: 95°C for 10 min, then 
40  cycles of 95°C for 15 s, and 60°C for 1 min. Data 
were obtained as Ct values (Ct = cycle number at which 
logarithmic PCR plots cross a calculated threshold line) 
and used to determine ΔCt values (ΔCt = (Ct of the target 
gene) – (Ct of the reference gene)). Data were expressed 
as arbitrary units using the following transformation 
(arbitrary units (AU) = 1000 × (2−∆ct)).
Protein extraction and immunoblotting
Monolayers of cells were placed on ice, washed with cold PBS, 
and then scraped into 100 μL of radioimmunoprecipitation 
assay (RIPA) buffer. For both tissue and cultured cell 
homogenates, samples were incubated at −80°C (10 min) 
on ice (30 min), and centrifuged at 4°C (10 min, 10,000 g). 
The supernatant was transferred to a fresh tube and total 
protein concentration was determined by a commercially 
available assay (Bio-Rad Laboratories). An amount of 
30–40 μg of protein was resolved on to an SDS-PAGE 
(acryl-amide percentage varied according to protein size). 
Proteins were transferred onto nitrocellulose membrane, 
Hybond ECL (GE Healthcare). Primary (anti-mTOR, 
anti-pSer2448 mTOR, anti-4E binding protein 1 
(anti-4E-BP1), anti-pThr37/46 4E-BP1, and anti-MuRF1 
were purchased from Cell Signaling) and secondary 
antibodies (Dako) were used at a dilution of 1/2000. 
Membranes were re-probed for β-actin or α-tubulin and 
primary and secondary antibodies used at a dilution of 
1/5000 (Abcam). Bands were visualized using ECL detection 
kit (GE Healthcare) and quantified using ImageJ software.
Statistical analysis
Statistical comparisons were performed using SigmaStat 
3.1 (Systat Software, Inc., Point Richmond, CA, USA). 
Data are presented as mean ± s.e.m. with statistical 
significance defined as P < 0.05. One- or two-way ANOVA 
followed by Bonferroni’s multiple comparison post hoc 
test was used to compare treatments. Statistical analysis 
on real-time PCR data was performed on ΔCt values and 
not fold-changes or AU.
Results
Rates of protein synthesis and protein degradation were 
assessed in C2C12 myotubes by measuring [3H]tyrosine 
incorporation into cellular proteins and measuring 
TCA-soluble radioactivity released into the culture 
media from cellular proteins pre-labeling with [3H]
tyrosine, respectively. CORT (62.5–1000 nM, 24 h) dose 
dependently decreased protein synthesis (Fig. 1A), while 
concomitantly increased protein degradation (Fig. 1B).
Consistent with the functional data, both CORT 
and 11DHC treatment (250 nM, 24 h) decreased C2C12 
myotube area (Fig. 1C and D). Importantly, the effects of 
11DHC were blocked by co-incubation with the selective 
Figure 1
Treatment of C2C12 myotubes with corticosterone (CORT: 62.5–1000 nM, 24 h) decreased [3H]tyrosine incorporation into cellular proteins (protein 
synthesis). (A) Paralleled by increased TCA-soluble radioactivity released into media from cells pre-labeled with [3H]tyrosine (protein degradation). 
(B) Data analyzed using one-way ANOVA. C2C12 myotube area was decreased following treatment with CORT (250 nM, 24 h) and 
11-dehydrocorticosterone (11DHC, 250 nM, 24 h). (C) The selective 11β-HSD1 inhibitor, PF-877423 (PF: 2.5 μM, 24 h), blocked the effects of 11DHC. 
Myotube area quantified from images using ImageJ software and analyzed using two-way ANOVA (C). Data expressed as mean ± s.e.m. of n = 6 
experiments. (**P < 0.01, ***P < 0.001 vs ctrl, $$$P < 0.001 vs 11DHC).
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Figure 2
[3H]tyrosine incorporation into cellular proteins in 
C2C12 myotubes (protein synthesis) was decreased 
by both corticosterone (CORT: 250 nM, 24 h) and 
11-dehydrocorticosterone (11DHC: 250 nM, 24 h). 
The selective 11β-HSD1 inhibitor, PF-877423 (PF: 
2.5 μM, 24 h), blocked the effects of 11DHC (A). 
Both CORT (250 nM, 24 h) and 11DHC (250 nM, 24 h) 
decreased IGF1 mRNA expression in C2C12 
myotubes (B), but Eif2b1 (C), 4E-BP1 (D), mTOR (E), 
Eif6 (F), and Ep300 (G) mRNA expression was 
unchanged. Serine-2448 phosphorylation of mTOR 
and threonine-37/46 phosphorylation of 4E-BP1 
were decreased by both CORT (250 nM, 24 h) and 
11DHC (250 nM, 24 h) in C2C12 myotubes, without 
effecting total protein levels. The effects of 11DHC 
on IGF1 expression, p-mTOR and p-4E-BP1 were 
reversed by PF-877423 (PF: 2.5 μM, 24 h) (B and H). 
Data expressed as mean ± s.e.m. of n = 6 
experiments, and analyzed using two-way ANOVAs. 
Western blot analyses were carried out on at least 
three different preps. (*P < 0.05, **P < 0.01, 
***P < 0.001 vs ctrl, $P < 0.05, $$P < 0.01 vs 11DHC).
11β-HSD1 inhibitor, PF-877423 (2.5 μM, 24 h) (Fig. 1C and 
D). A concentration of 250 nM was used, as this was the 
lowest concentration of CORT that resulted in statistically 
significant changes in rates of both protein synthesis and 
protein degradation.
Both CORT and 11DHC treatment (250 nM, 24 h) 
decreased [3H]tyrosine incorporation into cellular 
 proteins (functional assessment of protein synthesis) in 
C2C12 myotubes (Fig.  2A), with the effects of 11DHC 
reversed by PF-877423 (2.5 μM, 24 h). Gene expression 
analysis revealed decreased mRNA expression of 
 insulin-like growth factor (IGF1) (a positive regulator 
of muscle size and mass) following both CORT and 
11DHC treatment (Fig.  2B). By contrast, the mRNA 
expression of the following key genes regulating protein 
metabolism were unchanged: eukaryotic translation 
initiation factor 2B (Eif2B1) (a GDP exchange factor 
important for initiation of protein synthesis), eukaryotic 
translation initiation factor 4E-BP1 (a repressor of protein 
translation), mTOR (a serine/threonine kinase that senses 
nutritional/environmental cues and couples that signals 
to regulate protein metabolism), eukaryotic translation 
initiation factor 6 (EiF6) (forms a complex with 40 s 
ribosomal subunit involved in translation initiation), and 
histone acetyltransferase p300 (EP300) (a key activator 
of translation) (Fig. 2C, D, E, F and G). Consistent with 
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decreased protein synthesis, a trend toward decreased 
activating serine-2448 phosphorylation of mTOR and 
threonine-37/46 phosphorylation of 4E-BP1 was observed 
following CORT and 11DHC treatment, without effecting 
total protein levels (Fig.  2H). Importantly, PF-877423 
reversed the effect of 11DHC on IGF1 mRNA expression, 
mTOR serine-2448 phosphorylation and 4E-BP1 
threonine-37/46 phosphorylation (Fig.  2A, B and H). 
PF-877423 treatment alone (2.5 μM, 24 h) was without 
effect on all parameters assessed.
Both CORT and 11DHC treatment (250 nM, 24 h) 
increased the TCA-soluble radioactivity released into the 
culture media from C2C12 myotube cellular proteins 
pre-labeled with [3H]tyrosine (functional assessment of 
protein degradation), with the effects of 11DHC reversed 
by PF-877423 (2.5 μM, 24 h) (Fig.  3A). In agreement, 
the mRNA expression of key muscle atrophy markers 
including: atrogin-1, MuRF1 (both E3 ubiquitin ligases), 
myostatin (MSTN) (a negative regulator of muscle mass), 
and forkhead box O3a (FOXO3a) (a transcription factor 
that regulates muscle mass), as well as MuRF1 total protein 
levels, were increased by both CORT and 11DHC, with 
PF-877423 blocking the effects of 11DHC on all these 
readouts (Fig.  3B, C, D, E and F). PF-877423 treatment 
alone (2.5 μM, 24 h) was without effect on all parameters 
assessed.
Myoblast proliferation is vital for the repair and 
maintenance of healthy muscle tissue. As such, we 
assessed the impact of both CORT and 11DHC on C2C12 
myoblast proliferation (Fig. 4A). CORT (100–500 nM, 48 h) 
decreased myoblast proliferation in a concentration- 
dependent manner. This was consistent with CORT-
mediated decreased expression of IGF1 and myogenic 
factor 5 (MYF5) (both of which positively regulate 
myoblast proliferation) (Fig. 4B and C), whereas MSTN (a 
negative regulator of myoblast proliferation) expression 
was increased following CORT treatment (Fig.  4D). 
Importantly, we observed no difference in CASP3 or 
CASP7 expression (key apoptotic effectors) (Fig. 4E and F), 
suggesting that the observed CORT-mediated decrease in 
myoblast proliferation was not simply down to increased 
myoblast apoptosis.
In contrast to CORT, 11DHC (100–500 nM, 48 h) 
(which relies on activation to CORT by 11β-HSD1) 
was without effect upon C2C12 myoblast proliferation 
(Fig.  4A), consistent with the 30-fold lower 11β-HSD1 
oxoreductase activity (11DHC to CORT) in myoblasts 
compared with myotubes (Fig.  4G). Incubation with 
IGF1 (10 ng/mL, 48 h), a known activator of myoblast 
proliferation, was used as a positive control in these 
experiments (Fig.  4A). The C2C12 myoblast prolifera-
tion data presented in Fig. 4 were measured using MTS 
and validated using BrdU (Supplementary Fig.  1, see 
section on supplementary data given at the end of this 
article).
To test whether these observations are relevant in 
a human setting, we treated human primary skeletal 
myotubes with cortisone (250 nM, 24 h). Consistent 
with our findings in the C2C12s, cortisone decreased 
protein synthesis ([3H]tyrosine incorporation into 
Figure 3
TCA-soluble radioactivity released into the culture media from C2C12 myotubes pre-labeled with [3H]tyrosine was increased by both corticosterone 
(CORT: 250 nM, 24 h) and 11-dehydrocorticosterone (11DHC: 250 nM, 24 h). The selective 11β-HSD1 inhibitor, PF-877423 (PF: 2.5 μM, 24 h), blocked the 
effects of 11DHC (A). Both CORT (250 nM, 24 h) and 11DHC (250 nM, 24 h) increased atrogin-1 (B), MuRF1 (C), Mstn (D), and FOXO3a (E) mRNA expression 
in C2C12 myotubes. Total protein levels of MuRF1 were also increased by both CORT and 11DHC (F). The effects of 11DHC on atrogin-1, MuRF1, Mstn, 
and FOXO3a mRNA expression as well as MuRF1 total protein levels was reversed by PF-877423 (PF: 2.5 μM, 24 h) (B, C, D, E and F). Data expressed as 
mean ± s.e.m. of n = 6 experiments, and analyzed using two-way ANOVAs. Western blot analyses were carried out on at least three different preps. 
(*P < 0.05, **P < 0.01 vs ctrl, $$P < 0.01 vs 11DHC).
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cellular proteins) (Fig.  5A) and increased protein 
degradation (radioactivity release into the culture media 
from cellular proteins pre-labeled with [3H]tyrosine) 
(Fig. 5B). The effects of cortisol (250 nM, 24 h) on protein 
synthesis and protein degradation in human primary 
myotubes were identical to that of cortisone (data not 
shown). Crucially, the effects of cortisone on protein 
synthesis and protein degradation were blocked by 
PF-877423 (2.5 μM, 24 h) (Fig.  5A and B). In agreement 
with the C2C12 data, cortisol (and not cortisone) was 
effective at suppressing myoblast proliferation (Fig. 5C).
Discussion
GC excess leads to skeletal muscle atrophy, however, 
the precise molecular mechanisms underpinning this 
observation is not completely understood. This has 
implications not only for the 1–2% of the population 
taking prescribed GCs (Wei et  al. 2004), but also where 
elevated endogenous GC levels contribute to the muscle 
atrophy seen with starvation (Wing & Goldberg 1993), 
sepsis (Tiao et al. 1996), and metabolic acidosis (May et al. 
1986). Here, we have characterized the impact of GCs 
and pre-receptor GC metabolism upon intramyocellular 
protein metabolism and myoblast proliferation.
We have shown that GCs decrease the rate of protein 
synthesis in both mouse C2C12 and human primary 
myotubes, in agreement with previously published 
reports (McGrath & Goldspink 1982, Savary et al. 1998, 
Shah et  al. 2000). Decreased activating serine-2448 
 phosphorylation of mTOR, a master regulator of protein 
metabolism, underpinned this finding. However, due to 
the vast number of environmental and nutritional cues 
that modulate mTOR activity, the mechanism(s) driving 
GC-mediated suppression of mTOR are likely to be complex 
(Laplante & Sabatini 2012). Despite this, we did observe 
decreased IGF1 mRNA expression in C2C12 myotubes. 
IGF1 is synthesized and secreted by skeletal muscle and 
acts autocrine, paracrine, and endocrine to stimulate 
Figure 4
C2C12 myoblast proliferation was decreased by 
corticosterone (CORT: 100 – 500 nM, 48 h), but not 
11-dehydrocorticosterone (11DHC: 100 – 500 nM, 
48 h), in a concentration-dependent manner (A). 
C2C12 myoblasts treated with CORT (100 – 500 nM, 
24 h) had deceased mRNA expression of IGF1 (B) 
and Myf5 (C), while Mstn expression was increased 
(D), whereas CORT was without effect on CASP3 
(E) and CASP7 (F) expression. Low oxoreductase 
activity of 11β-HSD1 (conversion of inactive 11DHC 
to active CORT) was detected in C2C12 myoblasts, 
with activity increasing across myocyte 
differentiation (G). Data expressed as mean ± s.e.m. 
of n = 6 experiments, and analyzed using one-way 
ANOVAs. (*P  <  0.05, **P  <  0.01, ***P  <  0.001 vs 
ctrl).
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mTOR, acting via AKT/PI3K pathway (Bodine et al. 2001, 
Rommel et  al. 2001). Importantly, we have previously 
shown GCs to decrease insulin/IGF1-stimulated activation 
of AKT (Morgan et al. 2009), consistent with the observed 
reduction in mTOR serine-2448 phosphorylation and 
suppressed protein synthesis reported here.
In agreement with attenuated protein synthesis, we 
observed a trend toward decreased 4E-BP1 threonine-37/46 
phosphorylation following GC treatment. 4E-BP1 directly 
interacts with eukaryotic translation initiation factor 4E 
(eIF4E), which is a limiting component of the multisubunit 
complex that recruits 40S ribosomal subunits to the 5′ end 
of mRNAs to be translated (Pause et al. 1994, Youtani et al. 
2000). Phosphorylation at threonine-37/46 facilitates 
in its dissociation from eIF4E, allowing activation of 
mRNA translation. Interestingly, there is evidence that 
mTOR directly phosphorylates 4E-BP1 at threonine-37/46 
(Gingras et  al. 1999). As such, the observed decrease in 
mTOR activation following GC treatment could explain 
the hypophosphorylated state of 4E-BP1, keeping this 
suppressor of RNA translation firmly associated with 
eIF4E, thereby attenuating protein synthesis.
Concomitant with suppressed protein synthesis, 
GCs augmented protein degradation in both mouse 
C2C12 and human primary myotubes, consistent with 
previously published reports (McGrath & Goldspink 1982, 
Biedasek et al. 2011). This was underpinned by increased 
mRNA and protein expression of the key E3 ubiquitin 
ligases: MuRF1 and atrogin-1. In addition, the mRNA 
expression of MSTN, a known negative regulator of 
muscle size and mass, was decreased by GC treatment. 
Importantly, the GC-mediated decrease in protein 
synthesis and increased protein degraded resulted in 
decreased C2C12 myotube area, consistent with the 
known muscle atrophying effects of GCs. Taken together, 
these data provide new mechanistic insight into the 
manner in which GCs mediate muscle-specific side effects 
associated with GC excess.
Previously, Biedasek and coworkers demonstrated that 
the non-selective HSD inhibitor, carbenoxolone, blocked 
cortisone-induced increase in protein degradation in human 
and murine myocytes induced by cortisone (Biedasek 
et al. 2011). In the current study, we have shown that the 
selective 11β-HSD1 inhibitor, PF-877423, not only blocks 
11DHC/cortisone-mediated increased protein degradation, 
but also 11DHC/cortisone-mediated suppression of protein 
synthesis in both C2C12 and human primary myotubes. 
These findings were validated at a molecular level, where 
11β-HSD1 inhibition also blocked the gene expression 
changes and post-translational protein phosphorylation 
events mediated by 11DHC in C2C12 myotubes. 
As the net effect of these functional changes was to reverse 
Figure 5
Treatment of differentiated human primary 
myotubes with cortisone (250 nM, 24 h) decreased 
[3H]tyrosine incorporation into cellular proteins 
(protein synthesis) (A), paralleled by increased 
TCA-soluble radioactivity released into the culture 
media from cells pre-labeled with [3H]tyrosine 
(protein degradation) (B). The selective 11β-HSD1 
inhibitor, PF-877423 (PF: 2.5 μM, 24 h), blocked the 
effects of cortisone on both protein synthesis and 
protein degradation. Proliferation of human 
primary myoblasts was decreased by cortisol 
(100–500 nM, 48 h) in a concentration-dependent 
manner, but not cortisone (100–500 nM, 48 h), (C). 
Data expressed as mean ± s.e.m. of n = 6 
experiments, and analyzed using one- or two-way 
ANOVAs. (*P < 0.05, **P < 0.01, ***P < 0.001 vs ctrl, 
$P < 0.05 vs cortisone).
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11DHC-mediated C2C12 myotube atrophy, these results 
underscore the potential for a selective 11β-HSD1 inhibitor 
for the treatment of muscle atrophy induced by GC excess.
Regulation of muscle mass is not only governed by 
protein turnover, but also by myoblast proliferation is 
also a key  factor in the repair and maintenance of healthy 
muscle tissue. Although previous studies have identified 
the highly potent synthetic GC, dexamethasone, to inhibit 
myoblast proliferation (te Pas et  al. 2000, Dong et  al. 
2013), the impact of endogenous GCs, and the role of pre-
receptor GC metabolism by 11β-HSD1 plays on myoblast 
proliferation has not been explored. In the present study, 
we found that active GCs (CORT/cortisol) to inhibit both 
rodent and human myoblast proliferative capacities, in 
agreement with the known effects of dexamethasone 
(te Pas et al. 2000, Dong et al. 2013). However, we found 
treatment with the inactive GCs (11DHC/cortisone) to 
be without effect upon myoblast proliferation, which 
a finding corroborated by 30-fold lower oxoreductase 
activity of 11β-HSD1 (11DHC to CORT) in myoblasts 
compared with myotubes. As such, it is plausible that GCs 
reactivated by 11β-HSD1 in mature myotubes regulate the 
proliferative capacity of undifferentiated myoblast pools 
located proximally in the muscle bed. This may represent 
an additional mechanism by which GCs and pre-receptor 
GC metabolism negatively regulate muscle mass.
Classical physiology studies have found transient 
GCs exposure to improve skeletal muscle performance 
(Schakman et  al. 2009). These ergonomic effects are 
mediated by the induction of the metabolic transcription 
factor Krüppel-like factor 15 (KLF15) (Morrison-Nozik 
et  al. 2015), defining a downstream pathway distinct 
from that resulting in GC-related muscle atrophy. These 
findings highlight the complex role GCs play in regulating 
of muscle physiology. Although, the transient effects of 
GCs have not been explored as part of the present study, 
investigation into the role of pre-receptor GC metabolism 
in the regulation of these ergogenic effects would be of 
great interest in future studies.
In conclusion, we have demonstrated that GCs are 
potent regulators of skeletal muscle protein homeostasis 
and myoblast proliferation. In addition, we have 
provided novel mechanistic insights into how GCs 
regulate these important metabolic pathways in vitro. 
Crucially, our data underscore the potential for the use 
of a selective 11β-HSD1 inhibitor to ameliorate muscle-
wasting effects associated with GC excess in exogenous 
and endogenous Cushing’s syndrome, starvation, sepsis, 
and metabolic acidosis.
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